(RTTNews) - Thursday, Merck & Co., Inc. (MRK) announced a research collaboration with Isomorphic Labs, an AI-first drug design and development company, to discover therapeutic small molecule candidates against an oncology target of strategic importance.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.
